<div id="readability-page-1"><p>Anthony Vendetti, an analyst from Maxim Group, maintained the Buy rating on cbdMD. The associated price target remains the same with $2.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Anthony Vendetti has given his Buy rating due to a combination of factors, including cbdMD’s solid top-line momentum and strategic expansion. He highlights that revenue in F2Q26 exceeded expectations, supported by resilient core product sales and initial contributions from the Bluebird Botanicals acquisition, even as regulatory shifts weighed on certain channels. He also views the new clinical healthcare channel as an important long-term opportunity that could open access to Medicare-related demand once federal frameworks for hemp-derived cannabinoids are more clearly defined.</p> <p>In addition, Vendetti underscores cbdMD’s balance sheet and liquidity as adequate, noting the company’s modest cash burn, lack of debt, and access to a $10M equity line that can help fund operations and strategic initiatives until expected cashflow breakeven in FY28. He believes integration of Bluebird is progressing, with potential cost synergies and cross-selling benefits ahead. Finally, his unchanged $2 price target reflects a DCF-based valuation and a projected EV/revenue multiple that still sits at a discount to peers, which he sees as attractive given cbdMD’s improving fundamentals and its positioning in a more tightly regulated CBD market.</p> </div>

YCBD

SBIO

LABU

<p>Analyst Anthony Vendetti from Maxim Group maintains a Buy rating on cbdMD with a $2 price target, citing strong revenue momentum and strategic expansion. He notes that F2Q26 revenue exceeded expectations, aided by core product sales and the Bluebird Botanicals acquisition. Vendetti highlights cbdMD's solid balance sheet, modest cash burn, and access to a $10M equity line. He sees long-term potential in the new clinical healthcare channel and believes integration of Bluebird will yield cost synergies. The $2 target reflects a DCF-based valuation at a discount to peers.</p>

Tip Ranks

cbdMD

iShares Biotechnology ETF

iShares Global Healthcare

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VG Health

CBDMD INC 8% SERIES A CUM CONVERT PFD STK USD25

Analyst Reiterates Buy on cbdMD, Maintains $2 Price Target Amid Solid Revenue Momentum and Strategic Expansion